SHS_280168 MEAP CUCB 16164

A Multicenter Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects with Active Ankylosing Spondylitis

A Multicenter Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects with Active Ankylosing Spondylitis
Phase IIb
NCT02963506
All Other
Rheumatology
Philip Mease, M.D.
UCB Pharmaceutical
Sephren Barrow
  • Swedish Medical Center